Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Corey Hunter

Interventional Pain Medicine New York, NY Medical Doctor

NPI 1194999532 CMS profile 144532

115 E 57Th St, Suite 1210, New York, NY 10022

Open in the dashboard

General payments

$446,320

590 records reported · program years 2019–2025

Research payments

$70,283

Paid to them · 298 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$124,719 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Corey Hunter of New York, NY is reported in the CMS Open Payments database as having received $446,320 across 590 general payments and $70,283 in research payments paid to them. Separately, studies naming them as principal investigator received $124,719 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $73,192 57
2024 General $4,618 19
2024 Research $1,570 2
2023 General $40,673 60
2023 Research $16,333 4
2022 General $140,011 153
2021 General $75,664 125
2021 Research $484 3
2020 General $51,000 47
2020 Research $7,343 74
2019 General $61,163 129
2019 Research $44,553 215

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Corey Hunter
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Corey Hunter were reported at $73,192. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Corey Hunter Interventional Pain Medicine median Middle half National median
2019 $61,163 $684 $216–$2,079 $163
2020 $51,000 $382 $122–$1,109 $114
2021 $75,664 $552 $167–$1,554 $132
2022 $140,011 $605 $187–$1,924 $149
2023 $40,673 $671 $195–$1,915 $160
2024 $4,618 $684 $206–$1,837 $164
2025 $73,192 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $243,175 375 payments
  2. Saluda Medical Americas, Inc. $56,521 51 payments
  3. Nalu Medical, Inc. $50,101 8 payments
  4. MML US, Inc. $37,363 30 payments
  5. Vertiflex, Inc. $31,022 29 payments
  6. Biotronik Inc. $9,271 5 payments
  7. Boston Scientific Corporation $7,711 6 payments
  8. NeuroOne Medical Technologies Corporation $3,150 1 payment
  9. Medtronic, Inc. $2,171 3 payments
  10. Vertex Pharmaceuticals Incorporated $1,641 6 payments
  11. Other $4,193 76 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $135,810 64 payments
  2. Compensation for serving as faculty or as a speaker for a medical education program $102,714 69 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $76,415 42 payments
  4. Travel and Lodging $43,300 141 payments
  5. Current or prospective ownership or investment interest $42,879 3 payments
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $26,807 13 payments
  7. Food and Beverage $16,025 255 payments
  8. Debt forgiveness $2,154 2 payments
  9. Honoraria $217 1 payment
Products named General payments · program years 2019–2025
  1. Nalu Neurostimulation System $50,101 8 payments
  2. Neuromodulation Dspsbls and Accs $43,590 43 payments
  3. PROCLAIM Neuromodulation $39,978 55 payments
  4. PROCLAIM Neuromodulation $39,656 65 payments
  5. ReActiv8 $37,363 30 payments
  6. Evoke $35,124 18 payments
  7. PROCLAIM Structural Heart $32,276 26 payments
  8. Superion ISS $31,022 29 payments
  9. Evoke SCS $21,398 33 payments
  10. IonicRF Generator $17,691 24 payments
  11. Other $49,147 217 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Biotronik Inc. $27,180 280 payments
  2. Abbott Laboratories $21,545 5 payments
  3. MML US, Inc. $17,903 6 payments
  4. Saluda Medical Americas, Inc. $3,656 7 payments

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

36

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$82

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

30.6%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cephalexin Generic 25 $51
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 11 $32

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 107 billing codes

Paid by Medicare

$192,835

Of which drugs: $11,011

Medicare patients

105

Average age 69

Services billed

5,957

68 women, 37 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 71%
High blood pressure 64%
Depression 51%
Ischemic heart disease 28%
Diabetes 23%
Cancer 19%
Osteoporosis 18%
Chronic kidney disease 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 21 236 $182
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 46 553 $162
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 42 494 $45
Injection, midazolam hydrochloride, per 1 mg J2250 Office 16 186 $20

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Prialt
  • TerSera Therapeutics LLC $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

888 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record